COA - Chromophobe and Oncocytic Tumor Alliance retweeted
New funding opportunity for the BHD research community!
This pilot grant program is designed to support bold, high-impact ideas that can deepen our understanding of Birt-Hogg-Dubé syndrome and improve outcomes for patients and families affected by the disease.
LOI submissions are due June 30.
More information: bit.ly/BHDProposals
#AcceleratingCures
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.
It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.
The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.
We are looking for someone to start ASAP! More information here:
postdocs.yale.edu/posts/2026…
Please help to spread the word and RT!
@DrChoueiri @VanAllenLab @tompowles1 @YaleCancer @YaleMed @SmilowCancer @kidneycan @OncoAlert @OncLive @KidneyCancer @A_P_S_A @cure_today @yalepathology @Yale_Urology @DrYukselUrun @MarkDSiegel1 @OncBrothers @DrKarineTawagi
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
For the 2nd year in a row, two talented #MsaouelLab post-docs @UTMDAnderson, Pankaj Chauhan & Kai Yu, co-mentored with @IamLinghua, Nizar Tannir&JJ Gao each received an @AACR scholar-in-training award for #Kidneycancer research #AACR26 honoring their dedication to #CancerResearch
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
The future of #kidneycancer care starts with your research! 🔬 We are looking to fund groundbreaking work that will move the needle for patients worldwide.
🗓️ Deadline: April 20, 2026
🔗 Apply here: bit.ly/4b4unPu
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
The KCA 2026 Award Program is still OPEN for applications! We’re funding:
✨ Trailblazer Awards
✨ Interdisciplinary Med Focus (w/ Korek Foundation)
✨ Chromophobe RCC (w/ @kidneycoa)
⏰ Due date: April 20th
🔗 Apply here: bit.ly/4b4unPu
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
Looking forward to this event tomorrow!
Please register and join us.
@kcCURE @KidneyCancer @kidneycan @OncLive @OncBrothers @OncoAlert @TargetedOnc @smart_patients
🚨Reminder🚨 Join us tomorrow at 9am for 'Advancing Care in #KidneyCancer: From Diagnosis to Survivorship,' hosted by @BraunMDPhD
➡️Agenda: bit.ly/4t1t5fZ
➡️RSVP: bit.ly/3OkdSqO
@YaleCancer @cure_today @kcCURE @RCCadvocate
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
9/ We’re grateful for the amazing team @DanaFarber_GU, @BrighamWomens, @BIDMChealth, and @OncoHost and for our patients for the opportunity to shed light on this rare and understudied RCC subtype!
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
8/ These findings extend our understanding of metastatic ChRCC biology and highlight mitochondrial metabolism both as a biomarker axis and a potential therapeutic vulnerability.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
7/ Our findings show that mitochondrial reprogramming in metastatic ChRCC is reflected in the circulating proteome capturing pathways linked to oxidative metabolism, redox balance, and metabolic adaptation. Validation in larger cohorts is needed to explore clinical implications.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
6/ Leveraging this mitochondrial signal, we developed a MitoCarta-restricted LASSO model. A 2-protein signature (ECI1, CKMT1A) distinguished ChRCC from ccRCC (AUROC 0.96) w/ consistent performance across clinical subsets and was associated with OS in metastatic ChRCC.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
4/ Among 7,289 quantified proteins, 209 differed between ChRCC and ccRCC. The ChRCC profile was characterized by widespread upregulation of mitochondrial pathways (β-oxidation, OXPHOS, stress response) with downregulation of known ccRCC markers like KIM-1.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
3/ We evaluated whether molecular and metabolic features can be leveraged for biomarker development and investigated circulating proteomic signatures associated w/ metastatic ChRCC. Findings were consistent w/ orthogonal data in 2 external cohorts (TCGA mRNA + tissue proteomics).
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
2/ Chromophobe RCC (ChRCC) is a biologically distinct subtype w/ limited effectiveness of available treatment options. In contrast to clear cell RCC, it is defined by whole-chromosome losses and a prominent mitochondrial phenotype. Metastatic biology is particularly understudied.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
1/🧵 Thrilled to share our new paper “A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma”. Grateful for this collaboration with the #HenskeLab under the mentorship of @VincentWenxinXu and @LisaHenske.
mdpi.com/2072-6694/18/6/1032
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
5/ Pathway enrichment analysis revealed that the ChRCC plasma proteome is dominated by mitochondrial and metabolic programs like β-oxidation, amino acid degradation, and oxidative phosphorylation. This indicates a strong mitochondrial signature detectable in circulation.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
At the @UCSDCancer Kidney Cancer Patient Summit, terrific lineup including @AdityaBagrodia, @YuWeiChenMD & @ADESAIONCMD. Dr. Bagrodia delivered clear, thoughtful comments on a variety of local therapies; Dr. Chen reminded us of the value in clinical trials like the @ALLIANCE_org STRIKE trial. The morning concluded with a riveting presentation from @kaydaustin, describing her journey. Was especially touched by the kinship she formed w other advocates incl our treasured @SWOG RCC Advocate @LauraEsfeller!
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
A beautiful vision from @DrRanaMcKay to bring together patients & providers at the @UCSDCancer Kidney Cancer Patient Summit. After initial comments from Dr. McKay & @AdityaBagrodia, inspiring words from the founder of @Joeyswings & the CEO of @kidneycan, @advocatekidneys. Terrific lecture thereafter from @cityofhope's very own @arafflemd on non-clear cell subtypes.
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
Hello everyone,
We are hosting our first kidney cancer symposium in Connecticut for individuals with kidney cancer and their caregivers.
Register here:
registration.curetoday.com/e…
Please re-tweet and help spread the word!
@YaleCancer @KidneyCancer @kidneycan @kcCURE @OncBrothers @OncoAlert @DrChoueiri @Uromigos @KidneyCAN4KCRS @OncLive @kaydaustin @smart_patients
Join us Sat., April 11 at 9am for our patient conference: Advancing Care in #KidneyCancer: From Diagnosis to Survivorship, hosted by @BraunMDPhD.
📍 The Greenberg Conference Center, New Haven
🗓 Saturday, April 11, 9am – 2pm
➡️RSVP bit.ly/3OkdSqO
@YaleCancer @cure_today @kcCURE @RCCadvocate
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
📢 We're accepting applications for #KidneyCancer research grants! Let us fund your work through:
🌟 Trailblazer Awards
🌟 Interdisciplinary Med Focus Award, w the Korek Foundation
🌟 Chromophobe RCC Focus Award, w @kidneycoa
Apply 🔗 bit.ly/4b4unPu
COA - Chromophobe and Oncocytic Tumor Alliance retweeted
📢 #KidneyCancer grant applications OPEN NOW!
Apply today and let's make the next research breakthrough together! 🔗 bit.ly/4gVe0FR
On offer:
🌟 Trailblazer Award
🌟 Interdisciplinary Med Focus Award, w the Korek Fdn
🌟 Chromophobe RCC Focus Award, w @kidneycoa
